Product Description
Mechanisms of Action: TRPV1 Antagonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for JNJ-88998377](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: China, Italy, Poland, Turkey, Unknown Location
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
88998377LYM1001 | P1 |
Recruiting |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2027-10-29 |
|
jRCT2031240200 | P1 |
Not yet recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2027-10-06 |